Imexpharm

Imexpharm OCF Margin

The Operating Cash Flow Margin of Imexpharm (IMP.VN) as of Oct 26, 2026 is 2.22 %. In the previous year, Operating Cash Flow Margin was 9.81 % — a change of -77.37% (lower).

OCF Margin

2.22 %

YoY

-77.37%

Last updated:

Operating Cash Flow Margin of Imexpharm is 2025 2.22 % . Operating Cash Flow Margin of Imexpharm was 2024 9.81 % . It decreases by -77.37% lower compared to the previous year.

The Imexpharm OCF Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

OCF Margin
Date
OCF Margin
Jan 1, 2018
11.15 VND
Jan 1, 2019
4.75 VND
Jan 1, 2020
5.34 VND
Jan 1, 2021
18.54 VND
Jan 1, 2022
23.03 VND
Jan 1, 2023
-2.03 VND
Jan 1, 2024
9.81 VND
Jan 1, 2025
2.22 VND
The Imexpharm OCF Margin history
YEAROCF MarginYoY
2.22 %-77.37%
9.81 %-583.22%
-2.03 %-108.81%
23.03 %+24.21%
18.54 %+247.15%
5.34 %+12.51%
4.75 %-57.41%
11.15 %+33.66%
8.34 %-0.44%
8.38 %+80.35%
4.65 %+167.10%
1.74 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Imexpharm Stock analysis

What does Imexpharm do? Imexpharm Corp manufactures and trades pharmaceuticals, medicinal chemicals, and botanical products, including antiseptics, traditional medicine, medical equipment, cosmetics, and supplemental food and drinks. The company provides packaging and warehousing services specifically for pharmaceutical storage. It also cultivates medicinal herbs. Imexpharm Corp serves the pharmaceutical industry and healthcare sector through its manufacturing, import, export, and trade operations, targeting businesses requiring medicinal products and services. The company's revenue streams include the sale of manufactured pharmaceuticals, imported and exported goods, and services such as packaging and warehousing. Its customers are businesses in the healthcare sector, including distributors and retailers of pharmaceuticals, medical equipment, and related products. The firm's operations span manufacturing, import, export, and trade, with additional services supporting the pharmaceutical supply chain. Imexpharm Corp's product portfolio covers a wide range of medicinal and health-related items, from antiseptics to supplemental food and drinks. The company's involvement in medicinal herb cultivation supports its production of traditional medicine and herbal-based products. This vertical integration enhances its ability to supply comprehensive solutions to healthcare businesses. Imexpharm is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Imexpharm stock

Operating Cash Flow Margin of Imexpharm is 2.22 % in 2025.

Operating Cash Flow Margin of Imexpharm changed from 9.81 % to 2.22 %, representing a -77.37% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow Margin Imexpharm since 2006 – with annual values, charts, and detailed analysis.

OCF margin measures the percentage of revenue converted into operating cash flow. It indicates cash generation efficiency from core business operations.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Cash Flow Margin's Imexpharm with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Cash Flow Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Cash Flow Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Imexpharm

All Key Metrics — Imexpharm